An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
A phase 3 trial testing Pelabresib, now recruiting.
Overview
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib is a phase 3 interventional study registered as NCT06401356, led by Novartis Pharmaceuticals, and recruiting when checked on 2026-09-11. Official title: An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib. Planned enrolment is 50 participants (estimated). The study started in 2024-08-13 and primary completion is expected in 2027-06-02. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialStudy of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Shares Novartis and the tag ctgov-ingest.
- TrialOpen-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Shares Novartis and the tag ctgov-ingest.
- TrialStudy Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Shares Novartis and the tag ctgov-ingest.
- TreatmentDJI136
Shares Novartis and the tag ctgov-ingest.
- TreatmentJDQ443
Shares Novartis and the tag ctgov-ingest.
- TreatmentAAA817
Shares Novartis and the tag ctgov-ingest.